The main thing for the week rounded up key news on drug delivery, regulation and patent disputes. The Government of the Russian Federation proposed a special procedure for the production and use of drugs for the treatment of individual genes without state registration. The Ministry of Health of Russia included primary cholangitis in the list of rare diseases, expanding it to 306 positions. Genentech and Novartis filed a lawsuit against Amneal and Kashiv BioSciences for infringing nine patents in the development of an omalizumab biosimilar. The Moscow Arbitration Court refused to grant a compulsory license to Novo Nordisk's inventions. A similar committee for health protection approved the heads of 15 expert councils and updated the areas of work of the experts. The Ministry of Health of Russia opposed the reduction from 30 to 10 days of the period, considering the risk of interruption of essential medical treatment. In Russia, "Tezild" was registered - the first drug to delay the transition of type 1 diabetes to the clinical stage. The state similarly rejected a bill on a mandate on increasing the listed marginal sale prices of pharmaceutical manufacturers from the list of VEDs. Elena Maksimkina pointed to a missed saving of more than 800 million rubles in the purchase of continuous glucose monitoring systems using the "extra second" mechanism. More details in the full version of Digest on our channel at MAX.

The main thing for the week rounded up key news on drug delivery, regulation and patent disputes. The Government of the Russian Federation proposed a special procedure for the production and use of drugs for the treatment of individual genes without state registration. The Ministry of Health of Russia included primary cholangitis in the list of rare diseases, expanding it to 306 positions. Genentech and Novartis filed a lawsuit against Amneal and Kashiv BioSciences for infringing nine patents in the development of an omalizumab biosimilar. The Moscow Arbitration Court refused to grant a compulsory license to Novo Nordisk's inventions. A similar committee for health protection approved the heads of 15 expert councils and updated the areas of work of the experts. The Ministry of Health of Russia opposed the reduction from 30 to 10 days of the period, considering the risk of interruption of essential medical treatment. In Russia, "Tezild" was registered - the first drug to delay the transition of type 1 diabetes to the clinical stage. The state similarly rejected a bill on a mandate on increasing the listed marginal sale prices of pharmaceutical manufacturers from the list of VEDs. Elena Maksimkina pointed to a missed saving of more than 800 million rubles in the purchase of continuous glucose monitoring systems using the "extra second" mechanism. More details in the full version of Digest on our channel at MAX.